This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bossavy, J.-P. Articles by Cadroy, Y. Search for Related Content PubMed PubMed Citation Articles by Bossavy, J.-P. Articles by Cadroy, Y. Related Collections Cardiovascular Pharmacology Anticoagulant mechanisms

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:2269-2275.)
© 1999 American Heart Association, Inc.

Thrombosis

Antithrombotic Efficacy of the Vitamin K Antagonist Fluindione in a Human Ex Vivo Model of Arterial Thrombosis

Effect of Anticoagulation Level and Combination Therapy With Aspirin

Jean-Pierre Bossavy; Kjell S. Sakariassen; Claire Thalamas; Bernard Boneu; Yves Cadroy

From Laboratoire de Recherche sur l'Hémostase et la Thrombose, Pavillon Lefèbvre, CHU Purpan, Toulouse France (B.B., Y.C.); Service de Chirurgie Générale et Vasculaire CHU Purpan, Toulouse, France (J.-P.B.); Department of Biology, Division of Physiology, University of Oslo, Oslo, Norway (K.S.S.); and Centre d'Investigation Clinique, CHU Purpan, Toulouse, France (C.T.).

Abstract—Thrombin is a main mediator of arterial thrombus formation, and its inhibition is an important antithrombotic strategy. However, the place of vitamin K antagonists among the different therapeutic strategies for preventing arterial thrombus formation is still debated. We studied the antithrombotic efficacy of the vitamin K antagonist fluindione in a human ex vivo model of arterial thrombosis and determined whether aspirin enhances fluindione efficacy. Ten healthy male volunteers were randomly assigned to receive fluindione, alone or in combination with aspirin (325 mg/d). Fluindione was given at increasing doses to give a stable international normalized ratio (INR) between 1.5 and 2.0 and between 2.1 and 3.0. We induced arterial thrombus formation ex vivo by exposing collagen- or tissue factor (TF)–coated coverslips in a parallel-plate perfusion chamber to native blood for 3 minutes at an arterial wall shear rate of 2600 s^-1. Platelet and fibrin deposition were measured by immunoenzymatic methods. Fluindione inhibited thrombus formation on TF-coated coverslips in a dose-dependent manner by 50% and 80% at INR 1.5 to 2.0 and INR 2.1 to 3.0, respectively (P<0.05). Fluindione in combination with aspirin inhibited TF-induced thrombus formation in a comparable manner. Collagen-induced thrombus formation was not reduced in subjects treated by fluindione. It was reduced by 50% to 60% in those treated with fluindione plus aspirin, regardless of the level of anticoagulation (P<0.05). Thus, the effectiveness of fluindione for preventing arterial thrombosis is dependent on the nature of the thrombogenic trigger. Fluindione is very effective in preventing TF- but not collagen-triggered thrombus formation. Aspirin enhances the antithrombotic effectiveness of fluindione, because combined treatment interrupts both TF- and collagen-induced thrombus formation.

Key Words: thrombosis • aspirin • anticoagulants

This article has been cited by other articles:

				P. C. Wong, E. J. Crain, C. A. Watson, A. M. Zaspel, M. R. Wright, P. Y. Lam, D. J. P. Pinto, R. R. Wexler, and R. M. Knabb Nonpeptide Factor Xa Inhibitors III: Effects of DPC423, an Orally-Active Pyrazole Antithrombotic Agent, on Arterial Thrombosis in Rabbits J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 993 - 1000. [Abstract] [Full Text] [PDF]

				Y. Cadroy, J.-P. Bossavy, C. Thalamas, L. Sagnard, K. Sakariassen, and B. Boneu Early Potent Antithrombotic Effect With Combined Aspirin and a Loading Dose of Clopidogrel on Experimental Arterial Thrombogenesis in Humans Circulation, June 20, 2000; 101(24): 2823 - 2828. [Abstract] [Full Text] [PDF]